Perspective Therapeutics, Inc. CATX
Perspective Therapeutics, Inc. (NYSE: CATX) is an oncology drug developer. Its lead program, VMT-alpha-NET, is in Phase 1 for Neuroendocrine tumors (Pb-212 alpha therapy). Its next catalyst on record is [212Pb]VMT01: Further VMT01 melanoma data expected in late 2026. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: [212Pb]VMT01 — Further VMT01 melanoma data expected in late 2026. (H2 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VMT-alpha-NET | NETs | radiopharmaceutical | Phase 1 |
| VMT01 | Melanoma | radiopharmaceutical | Phase 1 |
| PSV359 | FAP-alpha solid tumors | radiopharmaceutical | Phase 1 |
| PSV594 | Undisclosed | radiopharmaceutical | Pre-clinical |
Recent results and decisions
- Nov 5, 2026positive Phase 1/2a trial of bamzireotide in SSTR2-expressing NETs shows 75% PFS at 18 months and 39% ORR in GEP-NET subgroup with SSTR2-positive target lesions.
Among these 57 patients: progression free survival (PFS) was 75% at 18 months; disease control was observed in 35 (92%) of 38 Cohort 2 patients and all 17 (100%) patients in Cohort 3; and responses were seen in 14 (37%) of 38 Cohort 2 patients and in 8 (47%) of 17 Cohort 3 patients.
Filing - Oct 23, 2026positive VMT-α-NET demonstrates ORR of 33% in Cohort 2 (5.0 mCi) and 50% in Cohort 3 (6.0 mCi) with 72% PFS at 18 months and no dose-limiting toxicities in Phase 1/2a trial.
ORR, including unconfirmed responses, was 33% in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20, as of September 10, 2026).
Filing - Oct 23, 2026positive Interim Phase 1/2a results for [212Pb]VMT-α-NET showed objective response rates of 33% in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20), with 72% progression-free survival at 18 months and no dose-limiting toxicities.
Objective response rate was 33% in Cohort 2 (5.0 mCi, n=46) and 50% in Cohort 3 (6.0 mCi, n=20, as of September 10, 2026).
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.